Paul Sogol
Endocrinology, Diabetes & Metabolism · Tarzana, CANPI 1538235718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Amgen at 26.1% of the total. Reporting peaked in 2019 at $1,317 and has fallen 97.6% since, to $31 in 2024.
Across 134 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$717
- AstraZeneca$320
- Novo Nordisk$313
- Lilly USA, LLC$150
- Boehringer Ingelheim$122
- Mannkind Corporation$111
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,749100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 25 | $717 |
| AstraZeneca(2 entities) | 16 | $320 |
| Novo Nordisk | 21 | $313 |
| Lilly USA, LLC | 8 | $150 |
| Boehringer Ingelheim | 5 | $122 |
| Mannkind Corporation | 6 | $111 |
| Johnson & Johnson | 4 | $104 |
| Astellas Pharma US Inc | 4 | $85 |
| Merck | 4 | $71 |
| Sanofi Pasteur Inc. | 5 | $70 |
| GSK | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Tactile Systems Technology Inc | 3 | $42 |
| Pfizer | 2 | $42 |
| Akebia Therapeutics Inc | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| AbbVie | 2 | $32 |
| Dexcom, Inc. | 1 | $31 |
| Abbott | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$125
How this compares
$2,749 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in Tarzana
- Yehuda HandelsmanTarzana$1M
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.